Patents Assigned to ZymoGenetics, Inc.
-
Patent number: 9146242Abstract: The present invention provides a method of measuring the levels of BLyS/APRIL heterotrimers (HT) in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with HT antagonists, either singly or in combination with other immune suppressive drugs.Type: GrantFiled: August 21, 2013Date of Patent: September 29, 2015Assignee: ZymoGenetics, Inc.Inventors: Stacey R. Dillon, Brandon J. Harder
-
Patent number: 9139651Abstract: The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.Type: GrantFiled: January 7, 2011Date of Patent: September 22, 2015Assignee: ZymoGenetics, Inc.Inventor: Janine Bilsborough
-
Patent number: 9011858Abstract: Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human IL-31. CDR regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein VH and VL domains are attached. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for inflammatory diseases. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides.Type: GrantFiled: May 15, 2013Date of Patent: April 21, 2015Assignee: ZymoGenetics, Inc.Inventors: Anthony W. Siadak, Janine M. Bilsborough, Shirley A. Rene
-
Patent number: 9005921Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.Type: GrantFiled: February 7, 2014Date of Patent: April 14, 2015Assignees: ZymoGenetics, Inc., Merck Serono S/AInventors: Kent Bondensgaard, Roland Beckmann
-
Patent number: 8992922Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: GrantFiled: June 27, 2013Date of Patent: March 31, 2015Assignee: ZymoGenetics, Inc.Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
-
Patent number: 8974783Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.Type: GrantFiled: February 7, 2014Date of Patent: March 10, 2015Assignee: ZymoGenetics, Inc.Inventors: Yue Yao, Janine Bilsborough
-
Patent number: 8969518Abstract: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.Type: GrantFiled: November 10, 2010Date of Patent: March 3, 2015Assignee: Zymogenetics, Inc.Inventors: Cameron S. Brandt, Jacob J. Kennedy, Wenfeng Xu, Eugene C. Yi, Brian A. Fox, Zeren Gao, Pallavur V. Sivakumar
-
Patent number: 8968732Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.Type: GrantFiled: December 19, 2013Date of Patent: March 3, 2015Assignee: ZymoGenetics, Inc.Inventors: Yue Yao, Janine Bilsborough
-
Patent number: 8956611Abstract: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF—R-Fc-fusion protein comprising the extracellular domain of BAFF—R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, (rituximab),ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.Type: GrantFiled: October 16, 2008Date of Patent: February 17, 2015Assignees: ZymoGenetics, Inc., Ares Trading S.A.Inventors: Rafael A. Ponce, Jr., Sergio Peano, Herve Broly, Hans Otto Lennart Graffner
-
Publication number: 20150037331Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions.Type: ApplicationFiled: September 26, 2014Publication date: February 5, 2015Applicant: ZymoGenetics, Inc.Inventors: Anthony W. Siadak, Shirley A. Rene
-
Patent number: 8926957Abstract: The present invention relates to predicting therapeutic response of treating patients suffering from itching and pruritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.Type: GrantFiled: March 13, 2013Date of Patent: January 6, 2015Assignee: ZymoGenetics, Inc.Inventors: Janine Bilsborough, Jane A. Gross
-
Patent number: 8907068Abstract: The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.Type: GrantFiled: May 21, 2008Date of Patent: December 9, 2014Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Zhi Chen, Steven D. Hughes, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavar V. Sivakumar, Margaret D. Moore
-
Patent number: 8900578Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.Type: GrantFiled: July 30, 2013Date of Patent: December 2, 2014Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
-
Patent number: 8871467Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: GrantFiled: June 5, 2013Date of Patent: October 28, 2014Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
-
Patent number: 8852591Abstract: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.Type: GrantFiled: March 27, 2008Date of Patent: October 7, 2014Assignee: Zymogenetics, Inc.Inventors: Rafael A. Ponce, Jr., Wayne J. Wallis, Matthew S. Holdren, Linda Zuckerman, Alisa M. Littau, Kirk P. Van Ness, Claudia Pena Rossi, Hans Otto Lennart Graffner
-
Patent number: 8834879Abstract: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.Type: GrantFiled: April 3, 2013Date of Patent: September 16, 2014Assignee: ZymoGenetics, Inc.Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
-
Publication number: 20140248661Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: ApplicationFiled: April 2, 2014Publication date: September 4, 2014Applicant: ZymoGenetics Inc.Inventors: Scott R. Presnell, Francis J. Grant, Emily C. Costerison, Theodore E. Whitmore
-
Patent number: 8822642Abstract: Compositions and methods relating to soluble dimeric proteins are disclosed. The dimeric proteins comprise first and second polypeptide fusions linked via a dimerizing domain, each polypeptide fusion comprising first and second monomer domains corresponding to a cytokine or an extracellular domain of a cell-surface receptor. The monomer domains may be positioned amino terminal and carboxyl terminal to the dimerizing domain. Alternatively, the monomer domains may be positioned in tandem, either carboxyl terminal or amino terminal to the dimerizing domain. The dimeric proteins are useful in methods for therapy, diagnosis, and research.Type: GrantFiled: June 7, 2011Date of Patent: September 2, 2014Assignee: ZymoGenetics, Inc.Inventors: Steven D. Levin, Margaret D. Moore, Craig D. Ostrander, Katherine E. Lewis, David W. Taft, Robert J. Rosler, Anitra Wolf, Megan M. Lantry
-
Patent number: 8816053Abstract: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.Type: GrantFiled: September 7, 2012Date of Patent: August 26, 2014Assignee: ZymoGenetics, Inc.Inventors: Kevin M. Klucher, Wayne R. Kindsvogel, Pallavur V. Sivakumar, Katherine E. Henderson
-
Patent number: 8815238Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.Type: GrantFiled: August 1, 2013Date of Patent: August 26, 2014Assignee: ZymoGenetics, Inc.Inventors: Mark W. Rixon, Jane A. Gross